NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer

Monday, March 30, 2026 · nanobiotix s.a.

AI Briefing

NANOBIOTIX announces positive results from a Phase 2 trial of JNJ-1900 (NBTXR3) in inoperable lung cancer.
Company's treatment combines ultrasound and MR-guided focused ultrasound to deliver chemotherapy directly to tumors.
Data to be presented at the 2026 European Lung Cancer Conference, further supporting potential of JNJ-1900 in treating advanced lung cancer.